FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165012777> ?p ?o ?g. }

• W3165012777 endingPage "668" @default.
• W3165012777 startingPage "667" @default.
• W3165012777 abstract "Background: Painful, recurring oral ulcers (OU) associated with Behçet’s syndrome negatively affect quality of life (QoL). Differences across sexes were reported in the frequency of disease manifestations, disease course, and response to colchicine. The phase 3, randomized, double-blind, placebo (PBO)-controlled RELIEF study showed overall efficacy of apremilast (APR) for OU associated with Behçet’s syndrome, including improvements in OU pain, disease activity, and QoL. Objectives: To evaluate the consistency of efficacy with APR in men and women with Behçet’s syndrome. Methods: Adults with active Behçet’s syndrome and ≥3 OU at randomization or ≥2 OU at screening and randomization, without active major organ involvement, were randomized to APR 30 mg BID or PBO during the 12-wk PBO-controlled phase. Randomization was stratified by sex. The primary endpoint was area under the curve for the number of OU through Wk 12 (AUC Wk0-12 ) to assess continued efficacy over the time period in a symptom that waxed and waned. Key secondary endpoints included OU pain, complete response (OU-free), maintenance of complete response, and QoL at Wk 12. Disease activity was also assessed using Behçet’s Syndrome Activity Score (BSAS) and Behçet’s Disease Current Activity Index Form (BDCAF). QoL was assessed using Behçet’s Disease QoL (BDQoL). Prespecified subgroup analyses in men and women were performed to assess treatment effect in primary and secondary endpoints. Results: Eighty men and 127 women were randomized and received ≥1 dose of study medication. Mean age was 38.7 yrs (men) and 40.8 yrs (women). Mean (SD) OU count at baseline was 3.4 (1.4) (PBO) and 3.7 (1.5) (APR) for men and 4.3 (3.2) (PBO) and 4.5 (4.5) (APR) for women. Greater improvements in favor of APR vs PBO were observed in AUC Wk0-12 in men and women (Figure 1). Consistency in efficacy with APR was observed between men and women, with greater reduction in pain and achievement of OU complete response (OU-free) and maintenance of response at Wk 12 vs PBO (Table 1). In men and women, consistent treatment effects in favor of APR vs PBO were observed for disease activity and QoL measures, although moderate treatment differences were observed in BDCAI (men/women) and BDQoL (men) (Table 1). Conclusion: Consistent treatment effects in favor of APR vs PBO in clinically relevant outcomes, including OU number and pain, OU complete response, and disease activity measures, were observed in men and women with OU associated with Behçet’s syndrome. Key Secondary Efficacy Outcomes at Wk 12 Men Women PBO (n = 40 ) APR (n = 40 ) Tx Difference [95% CI] PBO (n = 63 ) APR (n = 64 ) Tx Difference [95% CI] OU CR, n/N (%) 8/40 (20.0) 21/40 (52.5) 32.6 [12.8, 52.4] 15/63 (23.8) 34/64 (53.1) 29.3 [13.2, 45.4] OU CR 6 + 6*, n/N (%) 1/40 (2.5) 10/40 (25.0) 22.8 [8.8, 36.8] 4/63 (6.3) 21/64 (32.8) 26.5 [13.6, 39.3] Pain (VAS)† -12.0 (4.8) -37.6 (4.9) -25.6 [-37.2, -14.1] -17.4 (4.4) -41.5 (4.3) -24.1 [-34.9, -13.3] BSAS† -1.3 (2.4) -14.4 (2.4) -13.1 [-18.8, -7.3] -7.7 (2.4) -19.7 (2.4) -12.0 [-18.0, -6.0] BDCAF† BDCAI -0.1 (0.3) -0.5 (0.3) -0.4 [-1.1, 0.4] -0.7 (0.3) -1.3 (0.3) -0.6 [-1.2, 0.0] Patient’s Perception of Disease Activity -0.2 (0.3) -1.4 (0.3) -1.2 [-1.9, -0.5] -1.0 (0.2) -1.8 (0.2) -0.9 [-1.4, -0.3] Clinician’s Overall Perception of Disease Activity -0.2 (0.3) -1.5 (0.3) -1.3 [-1.9, -0.7] -1.0 (0.2) -1.7 (0.2) -0.7 [-1.3, -0.2] BDQoL† -0.7 (1.0) -2.2 (1.0) -1.5 [-3.8, 0.8] -0.3 (0.9) -4.4 (0.9) -4.1 [-6.3, -2.0] LOCF analyses. *Proportion of patients achieving an OU CR by Wk 6, and remaining OU-free for ≥6 additional wks during the 12-wk PBO-controlled treatment phase. †LS mean (SE) change from baseline. BSAS = Behçet’s Syndrome Activity Scores; BDCAF = Behçet’s Disease Activity Form; CR = complete response; n = number of patients randomized to treatment; Tx = treatment. Acknowledgements: This study was funded by Celgene. Additional analyses were funded by Amgen Inc. Writing support was funded by Amgen Inc. and provided by Kristin Carlin, RPh, MBA, of Peloton Advantage, LLC, an OPEN Health company. Disclosure of Interests: Gulen Hatemi Speakers bureau: AbbVie, Novartis, and UCB, Grant/research support from: Celgene, Alfred Mahr Speakers bureau: Chugai and Roche, Consultant of: Celgene and Chugai, Mitsuhiro Takeno Speakers bureau: AbbVie, Esai, and Mitsubishi-Tanabe, Consultant of: Celgene, Grant/research support from: Novartis, Doyoung Kim: None declared, Melike Melikoglu: None declared, Sue Cheng Employee of: Amgen Inc., Sven Richter Employee of: Amgen Inc., Shauna Jardon Employee of: Amgen Inc., Maria Paris Employee of: Amgen Inc., Mindy Chen Employee of: Amgen Inc., Yusuf Yazici Consultant of: Bristol-Myers Squibb, Celgene, Genentech, and Sanofi" @default.
• W3165012777 created "2021-06-07" @default.
• W3165012777 creator A5007097704 @default.
• W3165012777 creator A5020895246 @default.
• W3165012777 creator A5040435098 @default.
• W3165012777 creator A5041749765 @default.
• W3165012777 creator A5046363214 @default.
• W3165012777 creator A5046434174 @default.
• W3165012777 creator A5048811341 @default.
• W3165012777 creator A5064136261 @default.
• W3165012777 creator A5071821634 @default.
• W3165012777 creator A5081240145 @default.
• W3165012777 creator A5081992002 @default.
• W3165012777 date "2021-05-19" @default.
• W3165012777 modified "2023-09-30" @default.
• W3165012777 title "POS0828 CONSISTENT EFFICACY WITH APREMILAST IN MEN AND WOMEN TO TREAT ORAL ULCERS ASSOCIATED WITH BEHÇET’S SYNDROME: PHASE 3 RELIEF STUDY RESULTS" @default.
• W3165012777 doi "https://doi.org/10.1136/annrheumdis-2021-eular.1926" @default.
• W3165012777 hasPublicationYear "2021" @default.
• W3165012777 type Work @default.
• W3165012777 sameAs 3165012777 @default.
• W3165012777 citedByCount "0" @default.
• W3165012777 crossrefType "journal-article" @default.
• W3165012777 hasAuthorship W3165012777A5007097704 @default.
• W3165012777 hasAuthorship W3165012777A5020895246 @default.
• W3165012777 hasAuthorship W3165012777A5040435098 @default.
• W3165012777 hasAuthorship W3165012777A5041749765 @default.
• W3165012777 hasAuthorship W3165012777A5046363214 @default.
• W3165012777 hasAuthorship W3165012777A5046434174 @default.
• W3165012777 hasAuthorship W3165012777A5048811341 @default.
• W3165012777 hasAuthorship W3165012777A5064136261 @default.
• W3165012777 hasAuthorship W3165012777A5071821634 @default.
• W3165012777 hasAuthorship W3165012777A5081240145 @default.
• W3165012777 hasAuthorship W3165012777A5081992002 @default.
• W3165012777 hasBestOaLocation W31650127771 @default.
• W3165012777 hasConcept C126322002 @default.
• W3165012777 hasConcept C141071460 @default.
• W3165012777 hasConcept C142724271 @default.
• W3165012777 hasConcept C159110408 @default.
• W3165012777 hasConcept C168563851 @default.
• W3165012777 hasConcept C1862650 @default.
• W3165012777 hasConcept C203092338 @default.
• W3165012777 hasConcept C204243189 @default.
• W3165012777 hasConcept C204787440 @default.
• W3165012777 hasConcept C27081682 @default.
• W3165012777 hasConcept C2776260265 @default.
• W3165012777 hasConcept C2779134260 @default.
• W3165012777 hasConcept C2779951463 @default.
• W3165012777 hasConcept C2781427535 @default.
• W3165012777 hasConcept C2781428731 @default.
• W3165012777 hasConcept C71924100 @default.
• W3165012777 hasConceptScore W3165012777C126322002 @default.
• W3165012777 hasConceptScore W3165012777C141071460 @default.
• W3165012777 hasConceptScore W3165012777C142724271 @default.
• W3165012777 hasConceptScore W3165012777C159110408 @default.
• W3165012777 hasConceptScore W3165012777C168563851 @default.
• W3165012777 hasConceptScore W3165012777C1862650 @default.
• W3165012777 hasConceptScore W3165012777C203092338 @default.
• W3165012777 hasConceptScore W3165012777C204243189 @default.
• W3165012777 hasConceptScore W3165012777C204787440 @default.
• W3165012777 hasConceptScore W3165012777C27081682 @default.
• W3165012777 hasConceptScore W3165012777C2776260265 @default.
• W3165012777 hasConceptScore W3165012777C2779134260 @default.
• W3165012777 hasConceptScore W3165012777C2779951463 @default.
• W3165012777 hasConceptScore W3165012777C2781427535 @default.
• W3165012777 hasConceptScore W3165012777C2781428731 @default.
• W3165012777 hasConceptScore W3165012777C71924100 @default.
• W3165012777 hasIssue "Suppl 1" @default.
• W3165012777 hasLocation W31650127771 @default.
• W3165012777 hasOpenAccess W3165012777 @default.
• W3165012777 hasPrimaryLocation W31650127771 @default.
• W3165012777 hasRelatedWork W2094293739 @default.
• W3165012777 hasRelatedWork W2105059445 @default.
• W3165012777 hasRelatedWork W2158273200 @default.
• W3165012777 hasRelatedWork W2611796762 @default.
• W3165012777 hasRelatedWork W2890098371 @default.
• W3165012777 hasRelatedWork W3119463521 @default.
• W3165012777 hasRelatedWork W4206955792 @default.
• W3165012777 hasRelatedWork W4236433139 @default.
• W3165012777 hasRelatedWork W4306253774 @default.
• W3165012777 hasRelatedWork W4317868882 @default.
• W3165012777 hasVolume "80" @default.
• W3165012777 isParatext "false" @default.
• W3165012777 isRetracted "false" @default.
• W3165012777 magId "3165012777" @default.
• W3165012777 workType "article" @default.